Ginkgo Bioworks
DNA
11.02
-0.45
-3.92%
Ginkgo Bioworks
US · DNA
#3438 by market cap
11.02
-0.45
-3.92%
Live - 5344 symbols - heartbeat 411s ago
· 2026-10-08 10:11
Pre-market
10.92
-4.80%
After-hours
11.31
-1.40%
Overnight
11.46
-0.09%
- Market cap
- 742.09M
- P/E (TTM)i
- -2.20
- P/Bi
- 1.77
- EPSi
- -5.64
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on DNA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -7.30, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year -25.06% YoY
Margins
- Gross margin
- 72.39%
- Operating margin
- -178.59%
- Net margin
- -183.81%
Key ratios & quality
- Altman Z-Scorei
- -7.30
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 54.18M | 76.66M | 313.84M | 477.71M | 251.46M | 227.04M | 170.16M |
| Gross profit | 54.18M | 61.05M | 184.15M | 273.49M | 197.45M | 182.50M | 123.18M |
| Selling & admin expenses | 29.48M | 38.31M | 862.95M | 1.43B | 385.03M | 246.16M | 183.29M |
| Research & development | 96.30M | 159.77M | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
| Operating profit | -71.60M | -137.03M | -1.83B | -2.21B | -768.20M | -487.73M | -303.88M |
| Pretax profit | -119.84M | -124.83M | -1.84B | -2.12B | -892.94M | -547.51M | -313.60M |
| Tax | 22.00K | 1.89M | -1.48M | -15.03M | -71.00K | -479.00K | -837.00K |
| Net profit | -119.86M | -126.72M | -1.84B | -2.11B | -892.87M | -547.03M | -312.76M |
| Basic EPS | 0 | 0 | -54 | -50 | -18 | -11 | -6 |
| Diluted EPS | -0.08 | -0.09 | -55.60 | -50.20 | -18.37 | -10.54 | -5.64 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 38.23M | 39.13M | 38.84M | 33.40M | 19.47M | 20.16M |
| Gross profit | 34.14M | 33.75M | 26.04M | 26.10M | 16.38M | 18.44M |
| Selling & admin expenses | 39.72M | 34.98M | 44.95M | 46.01M | 37.83M | 30.78M |
| Research & development | 70.92M | 53.37M | 69.35M | 50.13M | 49.92M | 46.21M |
| Operating profit | -76.51M | -54.60M | -88.27M | -70.05M | -71.37M | -58.55M |
| Pretax profit | -83.22M | -53.48M | -80.75M | -81.39M | -76.14M | -57.19M |
| Tax | 88.00K | -283.00K | 1.00K | -643.00K | -80.00K | 128.00K |
| Net profit | -90.96M | -60.30M | -80.76M | -80.75M | -82.59M | -46.71M |
| Basic EPS | -2 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.68 | -1.10 | -1.45 | -1.42 | -1.39 | -0.75 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | -- | 426.54M | 1.72B | 1.45B | 1.00B | 602.74M | 471.84M |
| Cash & ST investments | -- | 380.80M | 1.55B | 1.32B | 944.07M | 561.57M | 422.62M |
| Inventory | -- | 2.74M | 3.36M | 4.36M | -- | -- | -- |
| Total assets | -- | 675.15M | 2.07B | 2.54B | 1.67B | 1.38B | 1.12B |
| Total current liabilities | -- | 73.22M | 134.76M | 172.96M | 163.86M | 107.27M | 95.97M |
| Short-term debt | -- | 485.00K | 747.00K | 29.33M | 17.47M | 28.97M | 22.81M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | 205,101,000.00 | 503,611,000.00 | 803,044,000.00 | 568,190,000.00 | 661,391,000.00 | 611,106,000.00 |
| Total equity | -- | 470.05M | 1.57B | 1.74B | 1.10B | 716.06M | 508.59M |
| Retained earnings | -- | -467.88M | -2.30B | -4.40B | -5.29B | -5.84B | -6.15B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 564.53M | 523.03M | 506.08M | 471.84M | 409.96M | 332.54M |
| Cash & ST investments | 516.92M | 473.69M | 461.86M | 422.62M | 373.46M | 302.16M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.29B | 1.23B | 1.19B | 1.12B | 1.03B | 990.05M |
| Total current liabilities | 115.67M | 96.72M | 115.28M | 95.97M | 79.60M | 72.74M |
| Short-term debt | -- | -- | -- | 22.81M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 646,036,000.00 | 618,057,000.00 | 629,382,000.00 | 611,106,000.00 | 589,922,000.00 | 569,762,000.00 |
| Total equity | 647.43M | 612.95M | 559.78M | 508.59M | 443.15M | 420.28M |
| Retained earnings | -5.93B | -5.99B | -6.07B | -6.15B | -6.23B | -6.28B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -44.66M | -135.83M | -253.82M | -252.20M | -295.50M | -319.59M | -171.06M |
| Depreciation & amortization | 10.76M | 13.86M | 29.08M | 42.55M | 70.51M | 63.02M | 58.99M |
| Free cash flow | -66.88M | -193.65M | -310.34M | -304.47M | -336.30M | -382.13M | -178.72M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -408.00K | 0 | -25.00M | 99.30M | 0 | 0 | 19.47M |
| Ending cash balance | 498.51M | 385.88M | 1.59B | 1.37B | 989.58M | 605.74M | 212.37M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -51.52M | -40.25M | -31.61M | -47.68M | -46.69M | -44.27M |
| Depreciation & amortization | 14.82M | 15.25M | 15.26M | 13.66M | 12.80M | 12.32M |
| Free cash flow | -59.14M | -40.29M | -31.61M | -47.68M | -48.62M | -46.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 9.15M | -- | -- |
| Ending cash balance | 355.41M | 251.35M | 156.96M | 212.37M | 188.67M | 172.02M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -27.44 | -192.06 | -130.06 | -63.02 | -60.34 | -51.08 |
| ROA %i | -- | -18.75 | -137.55 | -91.45 | -42.47 | -35.96 | -25.05 |
| ROIC %i | -- | -26.50 | -188.08 | -114.81 | -54.01 | -46.42 | -31.45 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -94.55 | -99.27 |
| EBIT margin %i | -216.70 | -159.74 | -584.94 | -444.06 | -355.07 | -241.11 | -184.30 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | 5.83 | 12.79 | 8.38 | 6.11 | 5.62 | 4.92 |
| Quick ratioi | -- | 5.54 | 12.61 | 8.09 | 5.87 | 5.44 | 4.66 |
| Debt / assetsi | -- | 2.52 | 1.11 | 17.43 | 14.37 | 33.96 | 39.29 |
| LT debt / equityi | -- | 3.58 | 1.48 | 23.80 | 20.22 | 61.28 | 82.01 |
| Interest coveragei | -48.50 | -51.34 | -773.60 | -20,012.20 | -9,600.51 | -5,823.55 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 106.58 | 48.58 | -10.23 | -29.11 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -57.70 | -43.55 | -49.97 | -51.08 | -55.82 | -56.29 |
| ROA %i | -32.81 | -22.05 | -25.41 | -25.05 | -26.17 | -26.19 |
| ROIC %i | -43.80 | -29.53 | -32.74 | -31.45 | -33.52 | -33.01 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -190.85 | -154.65 | -217.58 | -184.30 | -203.75 | -235.93 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.88 | 5.41 | 4.39 | 4.92 | 5.15 | 4.57 |
| Quick ratioi | 4.70 | 5.14 | 4.20 | 4.66 | 4.95 | 4.33 |
| Debt / assetsi | 33.60 | 34.84 | 35.56 | 39.29 | 39.76 | 40.82 |
| LT debt / equityi | 67.12 | 69.96 | 75.54 | 82.01 | 92.68 | 96.15 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 10:11:07 · For reference only, not investment advice and not tailored to your situation.